Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)

NCT05351736 is registered in ClinicalTrials.gov with Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico as lead sponsor.

NCT NCT05351736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05351736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)
Lead sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase
Phase 4
Overall status
Unknown status
Start date
January 26, 2022
Completion date
April 28, 2024
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia